Clinical utility of a molecular signature in inflammatory demyelinating disease
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received May 22, 2018
- Accepted in final form October 2, 2018
- First Published November 9, 2018.
Author Disclosures
- Andrew R. Pachner, MD,
- Krista DiSano, MS, PhD,
- Darlene B. Royce, BS, RLATg and
- Francesca Gilli, MS, PhD
- Andrew R. Pachner, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
EMD-Serono, Genzyme, Roche, Novartis, Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Krista DiSano, MS, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Darlene B. Royce, BS, RLATg and
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Francesca Gilli, MS, PhD
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Hitchcock Foundation Pilot Research project (2) Hitchcock Foundation Scholarship
NONE
NONE
NONE
NONE
NONE
NONE
- From the Department of Neurology, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH.
- Correspondence
Dr. Gilli Francesca.Gilli{at}dartmouth.edu
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Sevil Yaşar and Dr. Behnam Sabayan
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Articles
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MSF. Sellebjerg, L. Börnsen, M. Khademi et al.Neurology, December 07, 2009 -
Articles
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosisJ. Kuhle, D. Leppert, A. Petzold et al.Neurology, February 23, 2011 -
Articles
Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosisC. E. Teunissen, E. Iacobaeus, M. Khademi et al.Neurology, April 13, 2009 -
Article
Intrathecal IgM production is a strong risk factor for early conversion to multiple sclerosisCatherina Pfuhl, Ulrike Grittner, René M. Gieß et al.Neurology, September 09, 2019